Management of pleural mesothelioma after first line checkpoint inhibitors

Cornedine Jannette de Gooijer, MD, Netherlands Cancer Institute, Amsterdam, Netherlands, gives an overview of the FLORA study, a real-world study assessing the efficacy of second-line platinum-based pemetrexed in patients with pleural mesothelioma, who have progressed on nivolumab and ipilimumab. Whilst this study investigated second line therapies retrospectively, the PEMMELA trial (NCT04287829) prospectively assesses second line treatments in this setting. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.